Improving Pain Therapeutics

Applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patient’s comfort.

We are a clinical stage specialty pharmaceutical company
focused on the reformulation of established therapeutics

Our proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for using opiates very often administered post-surgically.

PRF - 110

Viscous clear oil-based solution that is instilled directly into the surgical wound

Providing localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated and its ease of use.

Market

The currently marketed non-opiate extended relief post-surgical topical products are based on a complicated formulation with either liposomes or an artificial polymer, and contain bupivacaine.

investors Relation

Nasdaq: PRFX

1.14

CHANGE: -5.79%

DAILY VOLUME: 58,622

LAST UPDATE: 04-12-2024 22:10

Send us a Message